Credit Suisse Ag Amicus Therapeutics, Inc. Call Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 12, 2021	SELL	$13.47 - $24.89 $133,353 - $246,411	-9,900 Reduced 30.18%	22,900 $529,000
Q3 2018 Nov 13, 2018	SELL	$11.6 - $16.54 $3.31 Million - $4.71 Million	-285,000 Reduced 89.68%	32,800 $397,000
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $11.5 Million - $15 Million	-876,800 Reduced 73.4%	317,800 $4.96 Million
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $5.08 Million - $6.32 Million	369,200 Added 44.73%	1,194,600 $18 Million
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $10.3 Million - $13.4 Million	825,400	825,400 $11.9 Million

313

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.77B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.